Information  X 
Enter a valid email address

Circassia's Tudorza meets primary endpoints in study

By BFN News | 07:17 AM | Monday 04 December, 2017


Circassia Pharmaceuticals has announced positive top-line results from the ASCENT phase IV post-marketing study of Tudorza in over 3,600 patients with moderate to very severe chronic obstructive pulmonary disease (COPD) and documented cardiovascular risk factors. The study was conducted by the company's partner AstraZeneca. Tudorza contains the long-acting muscarinic antagonist (LAMA) aclidinium bromide administered via Pressair inhaler. The ASCENT study met its primary efficacy endpoint, with Tudorza demonstrating statistically significant reductions in the rate of moderate or severe COPD exacerbations compared with placebo. In addition, Tudorza met its primary safety endpoint, demonstrating a favourable cardiovascular safety profile, with the time to patients experiencing a first major adverse cardiovascular event similar to placebo. Cardiovascular disease is the most common and significant comorbidity of COPD. Circassia said a full evaluation of the ASCENT data was ongoing and the results would be submitted for presentation at a forthcoming medical Story provided by StockMarketWire.com

a d v e r t i s e m e n t